Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 30, 2012

Primary Completion Date

September 6, 2017

Study Completion Date

March 19, 2026

Conditions

Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic CarcinomaStage III Pancreatic Cancer AJCC v6 and v7Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG

Dasatinib

Given PO

DRUG

Erlotinib Hydrochloride

Given PO

DRUG

Gemcitabine Hydrochloride

Given IV

Trial Locations (1)

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH